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ABSTRACT
Objective: Existing estimates of human immunodeﬁciency
virus (HIV)-related health state utilities are inadequate for
comparing alternative treatments on the basis of regimen-
speciﬁc attributes such as dosing requirements or tolerability.
The objective of this study was to examine the marginal
impact of dosing, adverse events (AEs), and other factors on
patients’ health state utilities.
Methods: Treatment naive and experienced HIV patients
participating in ﬁve open-label trials of highly active anti-
retroviral therapy (HAART) completed the 36-Item Short
Form Health Survey (SF-36) instrument at various time
points. SF-36 responses were converted to utilities using
a previously reported algorithm. Expected utilities were
estimated as a function of patient demographics, regi-
men attributes, disease status, and AEs using a mixed-
effects maximum likelihood model. Mean utilities for ﬁve
HIV health states were derived from predicted patient
utilities.
Results: Negative predictors of utility included greater age
(-0.001), prior acquired immune deﬁciency syndrome-
deﬁning events (-0.036), female gender (-0.038), and injec-
tion drug use (-0.056; P < 0.01 for all). Utility also depended
on CD4+ cell count (P < 0.01), but not the presence of unde-
tectable viral load. Regimen attributes were marginally asso-
ciated with changes in utility. Depression was associated with
the largest decrease in utility (-0.054, P < 0.001) among the
AEs examined. Using the model to generate predicted utilities
from the sample provided mean estimates ranging from
0.742 (SD 0.058) to 0.798 (0.052) for CD4+ counts between
0 and 99 and 500 cells/mm3, respectively.
Conclusions: HIV patients’ health-related quality of life may
be substantially affected by clinically relevant patient-,
disease-, and treatment-related factors, such as injection drug
use, disease status, food/drink restrictions, and AEs.
Keywords: AIDS, health state utility, methods, preference-
based measures, SF-36.
Introduction
Infection with human immunodeﬁciency virus (HIV),
the virus that causes acquired immune deﬁciency syn-
drome (AIDS), is known to cause substantial decreases
in health-related quality of life [1–3]. Although assess-
ment methods vary considerably, studies conducted
among individuals infected with HIV have consistently
shown a positive relationship between health state
utilities and CD4+ cell count, a marker of disease
progression; that is, as CD4+ count falls, so does utility
[2,4–7]. Thus, effective drug therapy and treatment
management strategies that slow the progression of
HIV infection have the potential to improve quality of
life as well as survival. Understanding the relationship
between health status and quality of life was particu-
larly important in the early development of HIV
therapy, when the tolerability of the limited number of
available agents was poor [3]. As the standard of care
evolved toward the use of better tolerated combination
therapy, quality of life information, in the form of
health state utilities, provided an important adjunct to
survival estimates in establishing the cost-effectiveness
of increasingly expensive—but also effective—treat-
ment strategies [5,8,9].
Most published models of HIV disease involve
either a traditional, state-based Markov cohort frame-
work [8,10–13] or a microsimulation [5,9,14–18], in
which CD4+ cell counts and, typically, AIDS-deﬁning
events (ADEs) are tracked for individuals over time.
With a cohort-based Markov approach, the impact of
ADEs or treatment side effects on utility is considered
only indirectly; that is, as a weighted average of utility
scores for patients in a particular health state who may
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or may not have experienced an ADE (or may have
experienced multiple ADEs) and who may be taking
different drug regimens. For example, Tengs et al. used
meta-analysis to derive a mean utility of 0.82 for the
“symptomatic HIV” state [19]. An individual classiﬁed
as symptomatic HIV with multiple, serious ADEs
would undoubtedly have a lower health utility than
an individual in the same health state with fewer and
less serious ADEs. On average, according to the Tengs
et al. analysis, a group of individuals with symptom-
atic HIV could be expected to report a health utility of
0.82. Most published studies of HIV utilities use an
estimation process that is consistent with a cohort
approach [1,2,6,7].
In contrast to cohort modeling, microsimulation
allows for an individualized approach where a base
health utility, which could vary by CD4+ cell count, is
modiﬁed with number and type of ADEs that occur for
each simulated patient as well as with the tolerability
of antiretroviral therapy. Unlike the Markov case, two
individuals that might be described as having symp-
tomatic HIV could have very different health utilities.
Freedberg et al. is the only widely available source of
HIV utilities than can accommodate both a base health
utility and an ADE-speciﬁc utility [5], and these utili-
ties have been incorporated into a Markov simulation
model which has been used to examine a number of
issues related to HIV care [5,9,14–18].
As Tengs et al. note, there is a substantial variation
in published estimates of HIV utility [19]. Partly this
can be explained by the treatment of ADEs in the
development of such estimates. The methods used
to estimate the utility weights also play a part—
assessment method (time trade-off, standard gamble,
rating scale, etc.), use of patients or nonpatients,
and scale bounds (e.g., perfect health to death). For
example, Schackman et al. found that patient-based
utilities for HIV health states were consistently higher
than community-based utilities [6]. Although the
patient- and community-based utilities in the Schack-
man et al. study were derived using different method-
ologies, the authors illustrate how the use of
alternative utility estimates can lead to markedly dif-
ferent conclusions within the context of a cost-
effectiveness analysis. These authors also found that
utilities derived via the rating scale method were sub-
stantially lower than standard gamble-based utilities, a
phenomenon that has been observed in other disease
areas [20–22].
Even within patient-based studies, substantial vari-
ability exists. Virtually all utility studies frequently
cited in published cost-effectiveness analyses were con-
ducted among or based on patient populations well
before the modern era of highly active antiretroviral
therapy (HAART) [2,6] or even before any type of
combination antiretroviral therapy was widely avail-
able [1,5]. Further, estimates of health state utilities
employed by the majority of recently published cost-
effectiveness evaluations of HIV therapy [9,11,14,16–
18,23] were derived from a single health status
question such as “How would you rate your current
state of health?,” scored on a 5-point Likert scale [5]
or “Overall, how would you rate your current
health?,” scored on an interval scale from 0 to 10 [6].
These were then converted to quality weights using
power transformations based on the time-trade-off and
standard gamble methods, respectively [24,25]. These
estimates do not reﬂect patients’ assessments across
various health status domains and their conversion
from the raw scores to rating scale values is somewhat
arbitrary. The power transformations that the authors
employed also may have biased the utility estimates
upward. Mrus et al. have shown, for example, that
linear formulas to transform visual analog scores to
standard gamble utilities perform better than the
power transformations employed in some of the
studies cited here [7].
Interest in modeling the long-term clinical and eco-
nomic outcomes of HIV disease certainly does not
appear to be waning. As knowledge about the disease
process and options for treatment continue to expand,
the approach to HIV care—and models describing
disease progression in those infected with HIV—also
evolves. The current standard of care for HIV therapy
(HAART) involves the use of three or more antiretro-
viral agents [26]. Typically, two agents from the class
of nucleoside/nucleotide reverse transcriptase inhibi-
tors (NRTIs) form the backbone of a HAART regimen,
with the third agent being either a non-nucleoside
reverse transcriptase inhibitor (NNRTI) or a protease
inhibitor (PI), the latter typically “boosted” by a low
dose of the PI, ritonavir. There are several combina-
tions of NRTIs, NNRTIs, and PIs that are generally
considered to be equivalent in terms virologic and
immunologic response [26]. Although new classes of
antiretroviral drugs generally represent clinically sig-
niﬁcant gains in health outcomes—fusion inhibitors
are a recent example [16,27,28]—comparisons among
existing classes of agents tend to focus on tolerability
and convenience, and available estimates of HIV util-
ities are inadequate for this purpose. Even the more
recent estimates of HIV health state utilities, in which
at least some patients received HAART, do not con-
sider speciﬁcally (or report) the effects of adverse
events (AEs), dosing ease, or other factors that may be
related to the process of therapy but not necessarily the
disease process [2,6,7,12]. As such, existing estimates
of HIV utilities may not capture adequately any differ-
ences in health-related quality of life accruing from
more tolerable or convenient HAART regimens.
The purpose of this study is to provide estimates of
HIV health state utilities based on a sample of patients
receiving care in the modern HAART era. Our alter-
native approach to the estimation of HIV utilities was
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speciﬁcally designed to address deﬁciencies in the
current literature. Data from multiple clinical trials are
used to develop a predictive model of utility that incor-
porates patient demographics, regimen characteristics,
disease indicators including ADEs, and drug-related
AEs. The derivation of the statistical model is
described, and an application of the model to derive
population- and individual-level utility estimates is
presented.
Methods
Data
Health-related quality of life and other information
collected from ﬁve Phase II, III, and IV clinical studies
served as the data source for the study [29–32]. All
the trials were randomized, open-label studies of
HAART regimens in the treatment of HIV-infected
adults over age 18 years between 1999 and 2003.
Three studies were conducted among antiretroviral-
naive individuals, and two were conducted among
antiretroviral-experienced individuals. The selected
trials were the only large, randomized studies con-
ducted by the sponsor in which quality of life was
assessed via the medical outcomes study 36-Item Short
Form Health Survey (SF-36) [33]. The SF-36 was nec-
essary for the calculation of health state utilities, as
summarized below. A brief description of each trial is
provided in Table 1.
Utility Scoring
All of the trials listed in Table 1 collected health-
related quality of life information via Version 1 of the
SF-36. Only subjects who completed at least one post-
baseline SF-36 questionnaire were included in the
analyses. Most subjects (95%) completed more than
one postbaseline SF-36 questionnaire. SF-36 values
from completed questionnaires were converted to
Table 1 Summary of clinical studies
Study number (phase) Treatment arms Patient type and number* Study length (time frame) SF-36 schedule
APV30003 (III) [29] • Fosamprenavir (700 mg) +
Ritonavir (100 mg) BID
• Fosamprenavir (1400 mg) +
Ritonavir (200 mg) QD
• Lopinavir/Ritonavir FDC
(400 mg/100 mg) BID
• PI-experienced
• Experiencing virologic failure
• N = 320
48 weeks (May 2001–
March 2003)
• Baseline
• Week 12
• Week 24
• Week 48
ESS30008 (III) [32] • Abacavir/Lamivudine FDC
(600 mg/300 mg) QD + baseline
PI or NNRTI
• Abacavir (300 mg) + Lamivudine
(150 mg) BID + baseline PI or NNRTI
• Antiretroviral experienced
patients
• N = 260
48 weeks (August 2002–
May 2004)
• Baseline
• Week 4
• Week 24
• Week 48
ESS40001 (II) [29] • Lamivudine (150 mg) BID +
Abacavir (300 mg) BID +
Stavudine (30 mg [<60 kg] or 40 mg
[>60 kg] BID
• Lamivudine (150 mg) BID +
Abacavir (300 mg) BID +
Efavirenz (600 mg) QD
• Lamivudine (150 mg) BID +
Abacavir (300 mg) BID +
Amprenavir (1200 mg) QD +
Ritonavir (200 mg) QD
• Antiretroviral naive
• N = 294
96 weeks (April 2000–
December 2002)
• Baseline
• Week 4
• Week 12
• Week 24
• Week 48
ESS40002 (IV) [30] • Stavudine (40 mg) BID +
Lamivudine (150 mg) BID +
Nelﬁnavir (1250 mg) BID
• Abacavir (300 mg) BID +
Lamivudine/Zidovudine FDC
(150 mg/300 mg) BID
• Lamivudine/Zidovudine FDC
(150 mg/300 mg) BID +
Nelﬁnavir (1250 mg) BID
• Antiretroviral naive
• N = 261
96 weeks (November
1999–November 2001)
• Baseline
• Week 4
• Week 8
• Week 24
• Week 48
• Week 72
• Week 96
ESS40013 (IV) [31] • Abacavir/Lamivudine/Zidovudine
FDC (300 mg/150 mg/300 mg)
BID + Efavirenz (600 mg)
QD for 96 weeks
• Abacavir/Lamivudine/Zidovudine
FDC (300 mg/150 mg/300 mg)
BID + Efavirenz (600 mg) QD for
48 weeks followed by Abacavir/
Lamivudine/Zidovudine FDC
(300 mg/150 mg/300 mg) BID
for 48 weeks
• Antiretroviral naive
• N = 448
96 weeks (March 2001–
October 2003)
• Baseline
• Week 48
• Week 96
*Number indicates randomized patients. Analysis population includes 287, 249, 274, 238, and 279 patients from APV30003, ESS30008, ESS40001, ESS40002, and ESS40013,
respectively.
BID, twice daily dosing; FDC, ﬁxed-dose combination; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; QD, once daily dosing; SF-36, 36-Item Short
Form Health Survey.
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preference-based utilities using a method proposed by
Brazier et al. [34]. This method uses a six-dimensional
health state classiﬁcation; these dimensions are physi-
cal functioning, role limitations, social functioning,
pain, mental health, and vitality. Because the SF-36
utilizes a 4-week recall period and several predictive
covariates of interest are available only after baseline,
only SF-36 questionnaires completed on or after week
4 were included in the analysis.
Variable Speciﬁcations
Demographic variables. Gender, age, race, region, and
injection drug use were included as ﬁxed effects in
the utility model. In the model, parameter estimates
compare female versus male. Age in years was calcu-
lated from the baseline study visit and included in the
model as a continuous parameter. Four race categories
were utilized in the trials; these included Hispanic,
black, white, and Asian/other. White race was used as
the reference case in the estimation. Region of residence
was speciﬁed as either Europe or “Rest of World”
compared to the USA. Prior injection drug use is a
well-recognized HIV risk factor and was included into
the model as a binary indicator (yes vs. no) [35,36].
HIV-related variables. Several previous studies have
shown a predictive relationship between HIV disease
status, as measured by CD4+ cell count, and health-
related quality of life and utilities in HIV [1,19,37–39].
CD4+ count was included as a binary variable (200
vs. >200 cells/mm3) because of the small amount of
data in some subgroups of interest. The break point of
200 cells/mm3 was chosen to correspond to common
deﬁnitions of HIV disease status.
In the natural (untreated) course of disease, contin-
ued viral replication eventually leads to decreases in
CD4+ cell count. Thus, one might expect health state
utilities to be related to HIV RNA as well as (or instead
of) CD4+ cell count and at least one study has found
such a relationship [40]. Nevertheless, an inverse rela-
tionship between CD4+ cell count and HIV RNA may
not be observed always, particularly for patients on
HAART. Individuals with low CD4+ cell counts may
also have relatively low HIV RNA and vice versa [16],
and evidence of a relationship between HIV RNA and
quality of life is mixed [41–44]. Plasma HIV RNA was
deﬁned in the model as an undetectable viral load
(plasma HIV RNA less than 50 copies/ml) versus
detectable to correspond with the stated goal of antiret-
roviral therapy to completely suppress the virus [26].
For each of the clinical trials in this study, plasma
HIV RNA and CD4+ cell count were collected at a
higher frequency than the SF-36 survey was adminis-
tered. This meant that multiple values for plasma HIV
RNA and CD4+ cell count were often present in the
4-week period preceding an SF-36 administration.
Because disease-state variables assessed closest to
SF-36 date are particularly applicable to economic
modeling, we elected to deﬁne both plasma HIV RNA
and CD4+ cell count in this manner for the ﬁnal
model. In addition, this speciﬁcation performed better
than alternatives such as averaging all prior values
within the 4-week recall period. By a similar assess-
ment, the variable representing ADEs was deﬁned as a
reported HIV-associated condition at any time before
SF-36 administration (vs. no ADEs before SF-36 date).
Baseline Centers for Disease Control and Preven-
tion (CDC) HIV/AIDS classiﬁcation and transition to
AIDS were also included in the model. Baseline CDC
HIV/AIDS classiﬁcation was deﬁned in the model as
AIDS versus non-AIDS at trial entry, where AIDS clas-
siﬁcation represents a CD4+ count of <200 cells/mm3
and/or the presence of a number of opportunistic infec-
tions [45]. Transition to AIDS (yes vs. no) reﬂects those
patients who were classiﬁed as non-AIDS at trial entry
and transitioned to AIDS before SF-36 survey comple-
tion. Because the decision to initiate HAART is often
based on patients’ disease status, treatment experience
at trial entry was considered related to HIV therapy.
Subjects were categorized as naive to therapy (no treat-
ment experience) versus experienced.
Regimen attributes. The clinical trials collected fre-
quency of dosing for the majority of, but not all,
enrolled subjects. Number of pills and food and/or
drink restrictions were not detailed in the clinical trial
data. When any treatment regimen information was
not speciﬁed in the data, it was imputed based on
treatment guidelines and package labels [26].
Dosing frequency was categorized as one or two
times per day, with twice per day (BID) as the reference
level. Where a regimen consisted of treatments with
differing frequency, the maximum frequency was
chosen. If all drugs in a patient’s regimen were dosed at
the same frequency, the regimen was considered sym-
metrical. Food and drink requirements were consid-
ered binary variables indicating treatments that must
be taken with food and/or drink or on an empty
stomach. Regimens that have no food or drink restric-
tions have a zero value for each of these variables.
Number of pills per day was summed across all anti-
retrovirals the patient was taking at the time of SF-36
administration, and this was included in the model as
a continuous variable.
AEs. Adverse events were recorded in the clinical trial
data by name and system organ class. System organ
class combines similar or related medical conditions or
problems into one of 24 groupings. Under this system,
nausea, for example, is grouped under “gastrointestinal
disorders” and fatigue is grouped under “general disor-
ders and administration site conditions.” We initially
considered using system organ class, but rejected this
Predicted HIV Utilities for Patients on HAART 1147
speciﬁcation because of poor model performance and a
lack of speciﬁcity for anticipated comparisons between
antiretroviral regimens. Instead, we included several
binary variables indicating the presence of speciﬁc AEs
in the 4-week period before SF-36 administration. AEs
were selected based on frequency of occurrence and
clinical relevance, and similar conditions were grouped
together. The following events were included in the
statistical model: elevated cholesterol or triglycerides,
myalgia or pain (includes peripheral neuropathy, arthri-
tis, and bone pain), nausea, nightmares, sinusitis
(include upper respiratory tract infection), weight loss
(includes decreased appetite), anemia or fatigue, diar-
rhea, vomiting, rash, depression, headache, dizziness,
drug hypersensitivity, and any other condition not
already speciﬁed. Other AEs included conditions such
as asthenia, pyrexia, and neutropenia, which occurred
at a rate of less than 0.66%. An indicator for any AE
grade 2 was also included in the model.
Statistical Model
A linear mixed-effects model was used to regress
explanatory variables against the converted SF-6D
utility scores. To assess the contribution of the four
classes of variables (demographics, HIV-related,
regimen characteristics, and AEs), we ran separate
nested models including different combinations of the
four groups and then used likelihood ratio tests to
check the contribution of each group separately. The
full model includes all explanatory variables as
described above.
In all models, the timing of SF-36 administration and
patient were included in the model as random effects to
control for unobserved, patient-speciﬁc characteristics
and multiple observations per patient. All other predic-
tors were included in the model as ﬁxed effects. Many
variables of interest could be speciﬁed in a number of
ways, as described above. When this was the case, we
investigated all feasible speciﬁcations for each variable
and choose that which resulted in the best model ﬁt
(based on the log likelihood ratio), minimized missing
data, and/or were most applicable to typical economic
modeling considerations. We also veriﬁed that no sig-
niﬁcant correlations existed between the variables.
Results of the mixed effects models estimated using
alternative deﬁnitions of the explanatory variables can
be found in the Web appendix to this article. The Web
appendix also contains reduced-form versions of the
model containing only demographic variables and
demographics plus CD4+ cell count variables.
To compare our model with previously published
estimates, we used the regression model to generate
predicted utilities from the clinical trial sample, using
the ﬁrst available observation for each patient. We then
calculated mean predicted utilities for ﬁve CD4+ cell
count ranges (<100, 100–199, 200–349, 350–499, and
500 cells/mm3), based on patients’ actual CD4+ cell
counts at the time of the observation.
P-values less than 0.05 were considered statistically
signiﬁcant. All statistical analyses were conducted
using SAS for UNIX software, Version 9 (SAS Institute,
Cary, NC).
Results
Demographic Characteristics
A total of 1327 subjects were included in the analyses,
and these subjects were evenly distributed across the
ﬁve studies. There were 4707 SF-36 records available
for the utility analysis, an average of 3.5 per subject.
Table 2 summarizes the demographic characteristics of
the analysis population. Approximately two-thirds of
the population was male, and nearly 90% of the popu-
lation was aged between 25 and 54 years. Although
the population was mostly white, Hispanics and blacks
were well represented. Most participants (71%)
resided in the USA. Approximately 5% reported injec-
tion drug use, and 11% were classiﬁed as having AIDS
at trial entry.
Of the 4707 available observations, 2995 (63.7%)
were associated with an undetectable viral load, and
4114 (87.4%) were associated with a CD4+ count
Table 2 Characteristics of the analysis population
Number (%)
Characteristic at study entry (n = 1327)
Female gender 290 (21.9)
Age (years)
18–24 82 (6.2)
25–34 432 (32.6)
35–44 530 (39.9)
45–54 215 (16.2)
55 68 (5.1)
Race
Hispanic 344 (25.9)
Black 401 (30.2)
White 559 (42.1)
Asian/other 23 (1.7)
Region
Europe 95 (7.2)
USA 943 (71.1)
Rest of world 289 (21.8)
Prior injection drug use 72 (5.4)
AIDS classiﬁcation at baseline 147 (11.1)
Antiretroviral naive 779 (58.7)
Characteristic throughout study (n = 4707)
CD4+ Count >200 cells/mm3 4114 (87.4)
HIV RNA < 50 copies/ml 3002 (63.4)
Dosing frequency
Once per day (QD) 334 (7.1)
Twice per day (BID)* 4373 (92.9)
Treatment taken with food and/or drink 2261 (48.0)
Treatment taken on empty stomach 1497 (31.8)
One or more prior ADEs 310 (6.6)
*All study drugs in the trials were dosed either QD or BID, but two patients received
TID regimen components as nonstudy drugs or protocol-allowable drug substitutions
for one study visit each, for a total of two observations. These observations were
coded as BID regimens for analysis purposes.
ADE,AIDS-deﬁning event; AIDS, acquired immune deﬁciency syndrome; HIV, human
immunodeﬁciency virus;TID, thrice daily dosing.
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>200 cells/mm3. The majority of HAART treatments
examined in the trials (92.9%) were BID regimens,
about half were symmetric, and half had some type of
food or drink restriction (either must be taken with
food or drink (48%) or must be taken on an empty
stomach (32%). ADEs were infrequent; only 310
(6.6%) of observations were accompanied by one or
more ADEs.
AEs
The reported frequency for the AEs included in the
model is shown in Table 3. Thirty-four percent of non-
baseline utility scores followed the recording of at least
one AE in the previous 4 weeks, and 16% followed at
least one AE of grade 2 (moderate) or above. Sinusitis
was the most common individual AE recorded (nearly
5%), and diarrheawas the secondmost common at 4%.
Utility Model Results
Coefﬁcients from the estimated linear mixed-effects
utility model are shown in Table 4. Positive (or nega-
tive) parameter coefﬁcients indicate that predicted
utility for individuals with that parameter is higher (or
lower) than individuals without the parameter (on a
scale of 0–1.0, where 0 = death and 1.0 = full health)
[46]. Negative predictors of utility included the follow-
ing: increasing age, female gender, injection drug
use, prior ADEs, treatment restrictions (taken with
food/drink, compared to no restrictions), presence of
myalgia or pain, depression, dizziness, an AE grade
2, and “other” AE. Black and Hispanic subjects had
signiﬁcantly higher predicted utility compared to
whites, and subjects with CD4+ count >200 cells/mm3
had higher predicted utility than those with lower
CD4+ cell counts.
Results of the likelihood ratio tests are shown in
Table 5. Examination of test results for the various
intermediate models suggests that each set of variables
explains some degree of variability in utility scores.
Further, the order in which variable groups enter the
model is unimportant.
Predicted Utility by CD4+ Range
To investigate the comparability of our model with
respect to previously published estimates, we produced
predicted values for several ranges of CD4+ cell count
from a reduced version of the model using the ﬁrst
postbaseline record for each subject. For example,
there were 76 patients whose CD4+ counts at the time
of their ﬁrst usable observation were between 0 and
99 cells/mm3. The average predicted utility for these 76
patients, using the regression model reported above,
was 0.742. This exercise was repeated for each CD4+
cell count group.
Table 6 summarizes the unadjusted SF-6D utilities,
the predicted utility values, and published estimates
Table 3 Adverse event frequencies (n = 4707)
Characteristic Number (%)
Presence of any AE 1600 (34.0)
Presence of any AE grade 2 760 (16.2)
Sinusitis 222 (4.7)
Diarrhea 183 (3.9)
Nausea 139 (3.0)
Myalgia or pain 126 (2.7)
Headache 93 (2.0)
Nightmares 92 (2.0)
Fatigue or anemia 86 (1.8)
Vomiting 57 (1.2)
Rash 57 (1.2)
Elevated cholesterol or triglycerides 52 (1.1)
Depression 49 (1.0)
Dizziness 45 (1.0)
Weight loss 24 (0.5)
Drug hypersensitivity 17 (0.4)
AE, adverse event.
Table 4 SF-6D utility model parameter estimates
Parameter Coefﬁcient (SE) P-value
Intercept 0.829 (0.022) <0.001
Demographic variables
Age in years -0.001 (0.000) 0.001
Female gender -0.038 (0.009) <0.001
Hispanic (vs. white) 0.019 (0.010) 0.046
Black (vs. white) 0.029 (0.009) 0.001
Asian or other race (vs. white) -0.033 (0.028) 0.235
Europe (vs. USA) -0.009 (0.016) 0.569
Rest of the world (vs. USA) 0.013 (0.009) 0.185
Injection drug use -0.056 (0.016) 0.001
HIV-related variables
AIDS classiﬁcation at baseline -0.002 (0.012) 0.897
Undetectable viral load
(HIV RNA < 50 copies/ml)
0.005 (0.004) 0.176
CD4+ count >200 cells/mm3 0.025 (0.006) <0.001
Transition to AIDS -0.002 (0.029) 0.946
Any ADE before SF-36 -0.036 (0.011) 0.001
Antiretroviral naive 0.003 (0.009) 0.699
Regimen attributes
Total number of prescribed pills per day 0.001 (0.001) 0.333
Dosing frequency once per day (vs. BID) 0.020 (0.015) 0.175
Symmetrical regimen -0.015 (0.009) 0.102
Treatment must be taken with food/
drink
-0.028 (0.011) 0.009
Treatment must be taken on empty
stomach
-0.001 (0.009) 0.899
Adverse events
Presence of AE Grade 2 -0.012 (0.005) 0.026
Elevated cholesterol or triglycerides 0.006 (0.015) 0.698
Myalgia or pain -0.027 (0.009) 0.003
Nausea -0.008 (0.009) 0.382
Nightmares -0.019 (0.010) 0.063
Sinusitis -0.006 (0.007) 0.359
Weight loss -0.015 (0.020) 0.466
Anemia or fatigue -0.013 (0.011) 0.241
Diarrhea -0.009 (0.008) 0.238
Vomiting -0.005 (0.014) 0.732
Rash -0.010 (0.013) 0.447
Depression -0.054 (0.015) <0.001
Headache -0.010 (0.011) 0.360
Dizziness -0.033 (0.015) 0.027
Drug hypersensitivity reaction -0.033 (0.025) 0.190
Other AE -0.012 (0.004) 0.005
-2 log likelihood = -6889.3.
ADE, AIDS-deﬁning event; AE, adverse event; AIDS, acquired immune deﬁciency
syndrome; BID, twice daily dosing; HIV, human immunodeﬁciency virus; SE, standard
error.
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from prior studies. The published estimates include
directly assessed standard gamble utilities [1,2], trans-
formed rating scale utilities [5,6], empirically derived
estimates that utilized a standard gamble transforma-
tion [12], and a meta-analysis that included an adjust-
ment for standard gamble assessment [19].
The predicted utilities decrease with decreasing
CD4+ count, as expected, but the raw (unadjusted)
utilities did not always follow the same pattern.
Expected utilities range from 0.742 (SD 0.058) for
CD4+ counts <100 cells/mm3 to 0.798 (SD 0.052) for
counts 500 cells/mm3 and higher. The range in mean
utilities across the ﬁve categories is similar to coefﬁ-
cient estimates from a reduced-form regression model
containing only demographics and CD4+ cell count
variables (see Web appendix, Table A3). For some
CD4+ cell counts, the raw utilities are lower than the
predicted utilities by 0.001 to 0.016 points. The ranges
from lowest to highest CD4+ cell categories—0.063
for the unadjusted utilities and 0.056 for the predicted
utilities—are within the ranges observed by others.
Discussion
To our knowledge, this is the ﬁrst effort to quantify the
impact of patient demographics, health status, regimen
characteristics, and AEs associated with antiretroviral
therapy on health state utilities in HIV. The results
Table 5 Likelihood ratio tests results
Model base (ﬁxed effects, -2 LL)
Variable group added difference* (DF) P-value
HIV-related Regimen attributes AEs
Demographics
(8, -6721.8)
50.6 (6)
P < 0.0001
19.5 (5)
P = 0.0016
118.9 (16)
P < 0.0001
Demographics + HIV
(14, -6772.4)
15.3 (5)
P = 0.0092
101.7 (16)
P < 0.0001
Demographics + regimen attributes
(13, -6741.3)
46.4 (6)
P < 0.0001
116.7 (16)
P < 0.0001
Demographics + AEs
(24, -6840.7)
33.4 (6)
P < 0.0001
17.3 (5)
P = 0.0040
Demographics + HIV + regimen attributes
(19, -6787.7)
101.6 (16)
P < 0.0001
Demographics + HIV + AEs
(30, -6874.1)
15.2 (5)
P = 0.0095
Demographics + regimen attributes + AEs
(29, -6858.0)
31.3 (6)
P < 0.0001
*Equals the difference in -2 log likelihood when variable group is added to the model base indicated in the left-most column. LL for ﬁnal model (demographics + HIV + Regimen
Attributes + AEs) with 35 degrees of freedom is -6889.3.
AE, adverse event; DF, degrees of freedom for the c2 distribution; HIV, human immunodeﬁciency virus; LL, log likelihood.
Table 6 Predicted and previously published estimates of HIV utility by CD4+ cell counta
Type of utility estimate
CD4+ range (cells/mm3)
0–99 100–199 200–349 350–499 500+
Unadjusted SF-6D
Utilitiesb,c, mean (SD)
0.750
(0.149)
0.746
(0.165)
0.777
(0.152)
0.809
(0.140)
0.782
(0.155)
Predicted SF-6D
Utilitiesb,c, mean (SD)
0.742
(0.058)
0.750
(0.058)
0.778
(0.053)
0.784
(0.059)
0.798
(0.052)
Directly derived SG utilities
Revicki et al. (1995)d [1] 0.796 0.796 0.822 0.804 0.804
Tsevat et al. (1999)e,f [2] 0.70 0.83 0.78 0.78 0.88
SG-based estimates
Freedberg et al. (1998)g [5] 0.79–0.81 0.87 0.94 not reported not reported
Tengs et al. (2002)d [19] 0.603 0.603 0.719 0.836 0.836
Schackman et al. (2002)d,h [6] 0.845 0.845 0.91 0.97 0.97
Mrus et al. (2003)i [7] 0.83 0.83 0.84 0.86 0.85
Simpson et al. (2004)j [12] 0.781 0.853 0.931 0.933 0.946
aPreviously published estimates are presented in the same number of signiﬁcant digits as originally reported.
bSample size equals 76, 162, 388, 276, and 398 for the 0–99, 100–199, 200–349, 350–499, and 500+ cells/mm3 groups, respectively.
cPredicted (adjusted) SF-6D scores based on subjects’ initial CD4+ cell counts.
dThe health state “AIDS” was mapped to CD4+ counts <200 cells/mm3; “Symptomatic HIV,” to 200–349 cells/mm3; and “Asymptomatic HIV” to 350 cells/mm3.
eAs reported by Mrus et al. (2003) [7].
fThe health state deﬁned as 201–500 cells/mm3 was mapped to 200–349 and 350–499 cells/mm3.
gExcludes opportunistic infections. Estimates were reported only for CD4+ counts 300 cells/mm3.
hOnly the patient-derived, transformed rating scale values are reported here.
iSG estimates based on linear transformation from rating scale values.
jAverage across all reported estimates within each CD4+ cell count range. Health states deﬁned by CD4+ counts <50 and 50–200 cells/mm3 were mapped to 0–99 and 100–199
cells/mm3, respectively.
AIDS, acquired immune deﬁciency syndrome; HIV, human immunodeﬁciency virus; N, sample size; SG, standard gamble.
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from our model are consistent with intuitive expecta-
tions regarding the relationship between disease status
and health state utilities; i.e., that utilities decrease as
CD4+ cell count declines. Contrary to some previous
research but compatible with our hypothesis, health
state utilities were not associated with recent HIV
RNA. Our results also support previous research
which suggests that women and injection drug users
have lower quality of life and health state utilities
[2,47]. Additionally, we have shown that regimen char-
acteristics such as food and drink requirements and the
occurrence of certain AEs signiﬁcantly impact patients’
health state utilities independent of disease status. That
is, regardless of disease stage, individuals’ utilities can
be negatively inﬂuenced by factors associated with
their treatment regimens.
Most variables in the model were associated with
seemingly small effects on quality of life, as measured
by the converted utility values. For example, each
10-year increase in age reduces predicted utility by
1%. Nevertheless, Walters and Brazier suggest that the
minimally important difference in utilities measured
by the SF-6D range from 0.010 to 0.048, with a mean
of 0.030 and a median of 0.032 [46]. Thus, even the
small coefﬁcients on parameters such as dizziness and
myalgia or pain indicate that these events may substan-
tially impact patients’ health-related quality of life.
The results of the regression model can be used to
predict health state utilities for HIV patients in two
ways. If individual patient-level data are available,
predicted values can be directly calculated using the
coefﬁcients listed in Table 4. If state-based utilities
are needed and patient-level data are unavailable, the
mean utilities in Table 5 can be used. These mean
values, calculated from the ﬁrst postbaseline observa-
tion available for each patient in the analysis data
set, show that predicted utility declines with worsening
health status, as would be predicted. The range
between the highest and lowest CD4+ cell count group
is rather narrow (5.6/100) and generally lower com-
pared to the estimates in Table 6. They are most
similar to the directly derived standard gamble utilities
assessed by Revicki et al. and Tsevat et al. (1999), as
modiﬁed and reported by Mrus et al. and the standard
gamble-based estimates reported by Mrus et al.
[1,2,7].
In addition to generating utility estimates for the
purposes of conducting economic evaluations relevant
to HIV care, the results of this study may aid patient
management by highlighting areas where appropriate
intervention might improve patients’ quality of life.
The two predictors of utility with the largest
coefﬁcients—and therefore the largest impact on
health utility—were injection drug use and depression.
In addition to the obvious health beneﬁts associated
with reducing injection drug use and improving mental
health status, addressing these issues has the potential
to signiﬁcantly improve quality of life. Although it is
difﬁcult to anticipate how an individual patient will
respond to a particular regimen, understanding the
relative impact of various attributes on quality of life
may be beneﬁcial starting point for discussions about
the possible side effects associated with HAART. An
optimistic interpretation of the relatively small scores
and lack of signiﬁcance for many of the AEs examined
in this study is that the events are relatively short-lived
and/or that patients successfully learn to adapt to them
so that they do not impact their quality of life as much
as might be expected. Unfortunately, we were unable
to investigate these phenomena within the clinical trial
data.
Our reliance on a clinical trial population intro-
duces some cautions when interpreting the results.
First, the clinical trial recruitment process may have
focused on participants who are healthier than other
individuals infected with HIV, such as those sampled
in the HIV Cost and Services Utilization Survey. In
addition, their health care is likely to be much more
intensely monitored than HIV-infected patients who
are not enrolled in clinical trials. This could explain,
in part, the small range in utilities between the lowest
and highest CD4+ cell count ranges produced by the
model. Second, the trials for this study were conducted
in an era where ADEs have had less of an impact on
HIV health status than was observed in the years
before the introduction of HAART. Third, some of the
conditions which are labeled in the regression model as
AEs may have been preexisting conditions or may not
have been related to a subject’s antiretroviral therapy.
Fourth, the regimens included in our sample tended
to be PI-based rather than NNRTI-based, with the
PI-based regimens more likely to be dosed BID and to
have dosing restrictions. Because the number of
patients receiving NNRTI-based regimens was small,
we were unable to determine whether drug class exerts
any independent effect on utilities after controlling for
other regimen characteristics. Finally, our sample con-
tained relatively few patients in the lowest CD4+ cell
count groups.
Despite their limitations, clinical trials provide a
unique environment for assessing the impact of
patient-, disease-, and treatment-related factors—and
particularly AEs—on health-related quality of life in
HIV disease. By pooling quality of life data across
studies representing treatment-naive and treatment-
experienced patients and HAART regimens including
all three primary classes of antiretrovirals, we were
able to estimate a predictive model that is sensitive to
speciﬁc HAART regimen characteristics. Although our
results should be generalized to relatively sick popula-
tions with some caution, the predictive model and its
associated health state utilities may be useful across a
wide variety of health outcomes applications, includ-
ing cost-effectiveness analysis, patient monitoring, and
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clinical decision-making. Future research replicating
these methods across highly experienced patients
and/or individuals in late-stage HIV infection is
strongly encouraged.
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